13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001799883
Total reported value
$287.9M
$287.9M
20 檔
68.1%
During the Q1 2026 filing period, 5AM Venture Management, LLC (CIK: 0001799883) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $287.9M across 20 reported positions.
In Q1 2026, 5AM Venture Management, LLC adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 3 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ERAS | Erasca Inc | Stock-Other | 15.66% | -15.66% | EXIT | |
| 2 | TRDA | Entrada Therapeutics Inc | Stock-Other | 14.21% | -3.84% | — | |
| 3 | TYRA | Tyra Biosciences Inc | Stock-Other | 10.94% | +0.48% | — | |
| 4 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 7.19% | +1.72% | — | |
| 5 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 6.41% | -6.41% | EXIT | |
| 6 | PHVS | Pharvaris N.V. | Stock-Other | 6.26% | +3.32% | — | |
| 7 | MPLT | Maplight Therapeutics Inc | Stock-Other | 5.36% | +6.47% | — | |
| 8 | TECX | Tectonic Therapeutic Inc | Stock-Other | 5.21% | +2.03% | — | |
| 9 | CLDX | Celldex Therapeutics Inc | Stock-Other | 4.38% | +2.05% | — | |
| 10 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 4.21% | +3.72% | — | |
| 11 | EYPT | Eyepoint Inc | Stock-Other | 3.76% | +1.46% | — | |
| 12 | SRZN | Surrozen Inc | Stock-Other | 3.13% | -0.69% | — | |
| 13 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 2.56% | +4.09% | — | |
| 14 | GHRS | GH Research PLC | Stock-Other | 2.24% | -2.24% | EXIT | |
| 15 | TARA | Protara Therapeutic Inc | Stock-Other | 1.98% | -0.16% | — | |
| 16 | BHVN | Biohaven Ltd. | Stock-Other | 1.74% | +2.08% | — | |
| 17 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 1.70% | +0.50% | — | |
| 18 | SKYE | Skye Bioscience Inc | Stock-Other | 1.65% | +0.68% | — | |
| 19 | RLYB | Rallybio CORP | Stock-Other | 0.73% | -0.73% | EXIT | |
| 20 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.70% | +1.12% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ERAS | Erasca Inc | +9.3% | -35.51% | Trim |
| 2 | TYRA | Tyra Biosciences Inc | +2.4% | — | Unchanged |
| 3 | 260 | Centessa Pharmaceuticals-adr | +1.8% | — | Unchanged |
| 4 | TECX | Tectonic Therapeutic Inc | +1.2% | — | Unchanged |
| 5 | TRDA | Entrada Therapeutics Inc | +1.1% | — | Unchanged |
| 6 | ARTV | Artiva Biotherapeutics Inc | +1% | — | Unchanged |
| 7 | ZNTL | Zentalis Pharmaceuticals Inc | +0.9% | — | Unchanged |
| 8 | SRZN | Surrozen Inc | +0.4% | — | Unchanged |
| 9 | CLDX | Celldex Therapeutics Inc | +0.1% | — | Unchanged |
| 10 | MPLT | Maplight Therapeutics Inc | +0.1% | — | Unchanged |
| 11 | GHRS | GH Research PLC | -0.1% | — | Unchanged |
| 12 | SLN | Silence Therapeutics Plc-adr | -0.2% | — | Unchanged |
| 13 | TARA | Protara Therapeutic Inc | -0.3% | — | Unchanged |
| 14 | SKYE | Skye Bioscience Inc | -0.6% | — | Unchanged |
| 15 | PHVS | Pharvaris N.V. | -0.7% | — | Unchanged |
| 16 | BHVN | Biohaven Ltd. | -0.9% | — | Unchanged |
| 17 | EYPT | Eyepoint Inc | -2.3% | — | Unchanged |
| 18 | CAMP | Camp4 Therapeutics CORP | -4.1% | — | Unchanged |
| 19 | VRDN | Viridian Therapeutics Inc | — | EXIT | Sold out |
| 20 | ELVN | Enliven Therapeutics Inc | — | EXIT | Sold out |
| 21 | ALXO | Alx Oncology Holdings Inc | — | NEW | New buy |
| 22 | RLYB | Rallybio CORP | — | NEW | New buy |
| 23 | ✓ | Rallybio CORP | — | EXIT | Sold out |
According to official SEC Form 13F filings, 5AM Venture Management, LLC reported a total U.S. public equity portfolio value of $287.9M across 20 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ERAS, TRDA, TYRA) accounted for 68.1% of total reported equity market value during Q1 2026.
Top New Position Initiated
ALXO
市值: $6.1M
Top Position Liquidated / Trimmed
VRDN
前期市值: $22.9M
During Q1 2026, 5AM Venture Management, LLC's top holdings by market value included ERAS (15.7%)、TRDA (14.2%)、TYRA (10.9%). The largest single position, ERAS, represented 15.7% of total portfolio value.
In Q1 2026, 5AM Venture Management, LLC made 6 total portfolio adjustments, initiating 2 new buys, adding to 0 positions, trimming 1 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.